Targeting final FDA approval of YUTREPIA™ after expiration of regulatory exclusivity on May 23, 2025Advancing pipeline of inhaled treprostinil ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...

Merck , known as MSD outside of the United States and Canada, today announced that new clinical and outcomes research data will be presented at the American College of Cardiology's Annual Scientific ...

?The Feinstein Institutes for Medical Research is the global scientific home of bioelectronic medicine, which combines ...

Corsair Pharma is planning a Phase 1 clinical trial of its treprostinil skin patch as a treatment for pulmonary arterial hypertension (PAH).

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the ...

Many unhealthy habits only affect us, but this particular habit can make animals ranging from dogs and cats to birds and fish ...

Columnist Jen Cueva has gotten more adept at listening to her body and making adjustments to manage her PH and leave room for joy.

Optum Rx has eliminated prior authorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...

Significant alterations in the structure and cellular composition of the distal lung are a defining characteristic of ...